ProImmune Limited – Trademark Portfolio
Entity Type: 16
ProImmune Limited holds 22 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 18 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 14 trademarks are registered and 1 is pending. Notable registered marks include PRO5, PROM2, PROT2, PROVE, and PROMAP. The owner is based in Oxford, OX44GA.
Magdalen Centre
Oxford Science Park
Oxford, OX44GA , GB
Showing of trademarks Trademarks
Trademark Classifications
ProImmune Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does ProImmune Limited have?
ProImmune Limited has 22 U.S. trademarks filed with the USPTO. Of these, 14 registered, 1 pending, 2 abandoned, 5 cancelled.
What trademark classes does ProImmune Limited file in?
ProImmune Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are ProImmune Limited's most well-known trademarks?
ProImmune Limited's registered trademark portfolio includes well-known marks such as PRO5, PROM2, PROT2, PROVE, and PROMAP. These are among 14 currently registered trademarks in the portfolio.
What is ProImmune Limited's trademark registration success rate?
ProImmune Limited has a 67% trademark registration rate, with 14 out of 21 resolved applications resulting in successful registration. Currently, 1 application is pending review.